Lupus myocarditis: marked improvement in cardiac function after intravenous immunoglobulin therapy

Rheumatol Int. 2010 Sep;30(11):1503-5. doi: 10.1007/s00296-009-1098-x. Epub 2009 Aug 21.


Intravenous immunoglobulin (IVIg) is emerging as the mainstay in the treatment of many autoimmune diseases, including systemic lupus erythematosus. IVIg has been found to be beneficial in myocarditis due to dermatomyositis/polymyositis, Kawasaki disease, and viral myocarditis in children. We report an 18-year-old man of active lupus with worsening cardiac systolic function who did not respond to pulse methylprednisolone and cyclophosphamide, but subsequently showed an improvement in his cardiac function after IVIg administration.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Heart Function Tests
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage*
  • Lupus Erythematosus, Systemic / complications*
  • Lupus Erythematosus, Systemic / drug therapy*
  • Lupus Erythematosus, Systemic / physiopathology
  • Male
  • Myocarditis / drug therapy*
  • Myocarditis / etiology
  • Myocarditis / physiopathology*


  • Immunoglobulins, Intravenous